MONTE ROSA THERAPEUTIC

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

26 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

13 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

07 Nov 2024 06:00:01 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

28 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

23 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

28 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

19 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

08 Aug 2024 06:00:02 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

08 Jul 2024 07:36:57 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

27 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

14 Jun 2024 07:45:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Leadership Team Promotions

30 May 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

30 May 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

21 May 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

16 May 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

15 May 2024 15:01:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 06:00:01 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

02 May 2024 15:01:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

14 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

11 Mar 2024 06:00:00 By Nasdaq GlobeNewswire